Champions Oncology
CSBR
25 hedge funds and large institutions have $27.6M invested in Champions Oncology in 2024 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 9 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
9% more funds holding
Funds holding: 23 → 25 (+2)
0.09% more ownership
Funds ownership: 41.36% → 41.45% (+0.09%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
12% less capital invested
Capital invested by funds: $31.5M → $27.6M (-$3.93M)
33% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 9
84% less call options, than puts
Call options by funds: $13K | Put options by funds: $80K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$406K |
| 2 |
Morgan Stanley
New York
|
+$132K |
| 3 |
MFIM
Mesirow Financial Investment Management
Chicago,
Illinois
|
+$72.5K |
| 4 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$71.7K |
| 5 |
Stifel Financial
St. Louis,
Missouri
|
+$65.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$406K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$145K |
| 3 |
AC
Aristides Capital
Louisville,
Kentucky
|
-$66.4K |
| 4 |
Bank of New York Mellon
New York
|
-$23.6K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$13K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Dimensional Fund Advisors
Austin,
Texas
| – | -$145K | -26,839 | Closed |
|
|
AC
27
Aristides Capital
Louisville,
Kentucky
| – | -$66.4K | -11,822 | Closed |
|
28
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$913 | -156 | -71% |
|
CSBR Hedge Fund Activity: Q1 2024 in Review
25 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Champions Oncology (CSBR) for Q1 2024, worth a combined $27.6M — down 12% from $31.5M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CSBR positions and 3 closed out — a net gain of 2 holders — while 6 added to existing stakes and 9 trimmed.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $406K. The largest seller was Ameriprise, exiting entirely with an estimated $406K sold.
- 25 institutional investors held Champions Oncology (CSBR) as of Q1 2024, up from 23 in Q4 2023.
- Funds reported $27.6M of Champions Oncology stock for Q1 2024, down 12% quarter-over-quarter.
- 5 funds opened new Champions Oncology positions in Q1 2024 and 3 closed out, a net change of +2 holders.
- The largest Champions Oncology buyer in Q1 2024 was Goldman Sachs, an estimated $406K added.
- The largest Champions Oncology seller in Q1 2024 was Ameriprise, an estimated $406K sold.
Based on aggregated 13F filings for Q1 2024.